Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma

Annals of the Academy of Medicine Singapore

Volumn 37, Issue 7, 2008, Pages 554-558

  Whay, Kuang Chia ^a   Ong, Simon ^a   Han, Chong Toh ^a   Siew, Wan Hee ^a   Su, Pin Choo ^a   Poon, Donald Y H ^a   Miah, Hiang Tay ^a   Chee, Kiat Tan ^b   Wen, Hsin Koo ^a   Kian, Fong Foo ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Cisplatin; Gemcitabine; Hepatitis B; Hepatocellular carcinoma

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 49449104680     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Seow A, Koh WP, Chia KS, Shi LM, Lee HP, Shanmugaratnam. Trends in Cancer Incidence in Singapore 1968-2002. Singapore: Singapore Cancer Registry. Report No 6.
2. nd ed. Singapore: Multimedia,9 1995.
3. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). Proc Am Soc Oncol 2007;abstr LBA1.
4. Graziadei I, Kelly T, Schirmer M, Geisen FH, Vogel W, Konwalika G. Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2′,2′-difluorodeoxycytidine on human hepatoma HepG2 cells. J Hepatol 1998;28:504-9.
5. Yang TS, Lin YC, Chen JS, Wang HM, Wang CH. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000;89:750-6.
6. Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002;94:3186-91.
7. Parikh PM, Fuloria J, Babu G, Doval DC, Awasthy BS, Pai VR, et al. A phase II study of gemcitabine and cisplatin in patients with advanced heptocellular carcinoma. Trop Gastroenterol 2005;26:115-8.
8. Yang TS, Chang WC, Lin YC, Chen JS, Liau CT, Yeh KY. A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma. Proc Am Soc Oncol 2003;22:abstr1351.
9. Newcombe RG, Altman DG. Proportions and their differences. In: Altman DG, Machin D, Bryant TN, Gardner MJ, editors. Statistics with Confidence. 2nd ed. London: British Medical Journal, 2000.
10. Simonetti RG, Leberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a system review of randomized controlled trials. Ann Oncol 1997;8:117-36.
11. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, et al. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis? Aliment Pharmacol Ther 1998;12:111-26.
12. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon-alpha2b/doxorubicin/5FU (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-8.
13. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona - 2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30.
14. Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421-7.